Zura Bio Limited Investigation - ZURA

Company
Zura Bio Limited (NASDAQ: ZURA)

Learn more about the Zura Bio Limited Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Zura Bio Limited Investigation Details

Zura Bio Limited shares fell a reported 68.2% in premarket trading after the Company reported that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet its primary endpoint of percent change from baseline in total abscess and inflammatory nodule count at Week 16 at either dose tested. Key secondary endpoints were also missed, leading the Company to discontinue development of tibulizumab for hidradenitis suppurativa. As recently as October 27, 2026, the Company reported in a Form 8-K that "TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026." On the same date, the Company filed a Form 10-Q reporting $3,913 in three-month and $13,302 in nine-month research and development spend for the program, as well as a Form S-3 registration statement asserting "we have not completed any clinical trials, and have no products approved for commercial sale." Additionally, between August 13 and August 18, 2026, Director Someit Sidhu filed Form 144 notices covering roughly 168,000 shares, selling 118,000 shares for approximately $658,083 in gross proceeds while representing no knowledge of undisclosed material adverse information. The investigation concerns whether Zura Bio Limited adequately disclosed the trial status and clinical results of tibulizumab ahead of discontinuing its hidradenitis suppurativa program.

Get Started